Roche's headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)

ODAC to de­bate Roche's Po­livy in first-line DL­B­CL fol­low­ing 2019 ac­cel­er­at­ed ap­proval

Once again the FDA’s pan­el of out­side on­col­o­gy ex­perts will have to weigh in on whether or not to grant an­oth­er in­di­ca­tion for Roche’s po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.